Target intelligence / Profile preview

Gastrointestinal epithelial and mucosal surfaces

Molecular classification
Other
01

Overview

The **gastrointestinal epithelial and mucosal surfaces** comprise the innermost layers of the digestive tract, including the epithelium (single layer of cells facing the lumen), the underlying lamina propria (connective tissue rich in immune cells and vasculature), and the muscularis mucosae (thin layer of smooth muscle)[1][4][6][5]. These surfaces are specialized for nutrient absorption, secretion of digestive enzymes and mucus, physical barrier protection, and coordination of immune responses. Several distinct cell types, such as absorptive enterocytes, goblet cells (mucus production), enteroendocrine cells (hormone secretion), and Paneth cells (innate immunity), contribute to these functions[2][3][1]. Dysfunction of the GI epithelium and mucosa is critical in many disease states, including cancer, autoimmune and inflammatory diseases, and infections. However, as a whole, the "gastrointestinal epithelial and mucosal surfaces" do not constitute a single drug target, and therapeutic strategies instead focus on modulating the function or integrity of distinct molecular components within these surfaces. "Gastrointestinal epithelial and mucosal surfaces" is not a specific molecular or receptor target but describes a composite anatomical structure composed of diverse cell types and functions. It cannot be considered a canonical, druggable target; any drug action is mediated through discrete molecular entities within this anatomical feature[1][6].

Other names
Gastrointestinal mucosaGI mucosaGI epitheliumintestinal epithelial surfacesluminal GI surfaces
02

Biological functions

Nutrient absorptionBarrier functionMucus secretionImmune defenseHormone and enzyme secretion
03

Disease associations

CancerInfectionInflammation (e.g., inflammatory bowel disease)MalabsorptionAutoimmune disease
04

Safety considerations

Nonspecific toxicity (due to broad targeting)Barrier dysfunction (often manifests as adverse effects, e.g., diarrhea, malabsorption, increased infection risk)
05

Biomarkers

Fecal calprotectin (for GI inflammation)Intestinal fatty acid-binding protein (I-FABP; enterocyte damage)Anti-tissue transglutaminase antibody (Celiac disease)Fecal occult blood (colorectal cancer screening)

Beyond the preview

Go deeper on Gastrointestinal epithelial and mucosal surfaces.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gastrointestinal epithelial and mucosal surfaces.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call